Drug Trial Radar · NCT00764907
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: Jul 8, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
4,000
Planned (sponsor's estimate)
Start
Nov 2002
Primary completion
Oct 2007
Sponsor
- Lead sponsor
- University Hospital, MotolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. A donor stem cell transplant may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving combination chemotherapy before the transplant helps stop the growth of cancer cells and stop the patient's immune system from rejecting the donor's stem cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying different risk-adjusted combination chemotherapy regimens in treating young patients with acute lymphoblastic leukemia.
Conditions
- Leukemia
Interventions
asparaginaseDrug
Given IV during reinduction
cyclophosphamideDrug
Given IV during reinduction
cytarabineDrug
Given IV during reinduction
daunorubicin hydrochlorideDrug
Given IV during reinduction
dexamethasoneDrug
Given IV or orally during reinduction
doxorubicin hydrochlorideDrug
Given IV during reinduction
etoposideDrug
Given IV during reinduction
ifosfamideDrug
Given IV during reinduction
leucovorin calciumDrug
Given IV during reinduction
mercaptopurineDrug
Given orally during reinduction
methotrexateDrug
Given orally during reinduction
prednisoneDrug
Given intrathecally during reinduction
thioguanineDrug
Given orally during reinduction
vincristine sulfateDrug
Given IV during reinduction
vindesineDrug
Given IV during reinduction
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival
- Event-free survival
- Overall survival
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Motol
Prague, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.